Found: 16
Select item for more details and to access through your institution.
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 9, p. 1045, doi. 10.1007/s40273-021-01027-4
- By:
- Publication type:
- Article
Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Lifetime Cost-Utility Analyses of Deferasirox in Beta-Thalassaemia Patients with Chronic Iron Overload.
- Published in:
- Clinical Drug Investigation, 2012, v. 32, n. 12, p. 805, doi. 10.1007/s40261-012-0008-2
- By:
- Publication type:
- Article
Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i.
- Published in:
- BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12269-8
- By:
- Publication type:
- Article
Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221081203
- By:
- Publication type:
- Article
Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 170, n. 3, p. 535, doi. 10.1007/s10549-018-4769-z
- By:
- Publication type:
- Article
Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer.
- Published in:
- Cancer Management & Research, 2021, v. 13, p. 8179, doi. 10.2147/CMAR.S325043
- By:
- Publication type:
- Article
Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer.
- Published in:
- Cancer Management & Research, 2018, v. 10, p. 1319, doi. 10.2147/CMAR.S163478
- By:
- Publication type:
- Article
Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?
- Published in:
- Cancer Management & Research, 2018, v. 10, p. 1015, doi. 10.2147/CMAR.S162714
- By:
- Publication type:
- Article
Patient experiences with patient-reported outcome measures in metastatic breast cancer trials: qualitative interviews.
- Published in:
- Journal of Patient-Reported Outcomes, 2022, v. 6, n. 1, p. 1, doi. 10.1186/s41687-022-00460-z
- By:
- Publication type:
- Article
Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR+, HER2–, PIK3CA‐Mutated Breast Cancer.
- Published in:
- Oncologist, 2021, v. 26, n. 7, p. e1133, doi. 10.1002/onco.13804
- By:
- Publication type:
- Article
Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2− breast cancer.
- Published in:
- Breast Journal, 2019, v. 25, n. 5, p. 880, doi. 10.1111/tbj.13345
- By:
- Publication type:
- Article
Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2– metastatic breast cancer.
- Published in:
- Breast Cancer: Targets & Therapy, 2018, v. 11, p. 69, doi. 10.2147/BCTT.S162841
- By:
- Publication type:
- Article
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7).
- Published in:
- Therapeutic Advances in Medical Oncology, 2020, v. 12, p. 1, doi. 10.1177/1758835920943065
- By:
- Publication type:
- Article
Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.
- Published in:
- PLoS ONE, 2017, v. 12, n. 6, p. 1, doi. 10.1371/journal.pone.0175920
- By:
- Publication type:
- Article
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEESA-3 Trial.
- Published in:
- 2022
- By:
- Publication type:
- journal article